Jack Kaye Sells 5,295 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 5,295 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $42.57, for a total value of $225,408.15. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,106,649.72. This trade represents a 16.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Trading Up 10.5%

NASDAQ QURE opened at $49.04 on Wednesday. The firm has a market capitalization of $3.09 billion, a P/E ratio of -14.09 and a beta of 0.98. The business has a fifty day simple moving average of $25.97 and a 200 day simple moving average of $22.47. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, analysts predict that uniQure N.V. will post -3.64 EPS for the current fiscal year.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported promising early results from its AMT-260 epilepsy program, with initial patients showing large seizure reductions and no treatment-related serious adverse events, supporting confidence in the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Several news outlets highlighted early AMT-260 data showing seizure reductions of 79% to 100% in three patients, which is helping fuel investor enthusiasm for the stock. Article Title
• Positive Sentiment: Analysts remain bullish on QURE, with recent upgrades and higher price targets reinforcing the view that the latest pipeline progress could create additional upside. Article Title
• Neutral Sentiment: The company also announced preliminary Phase I/IIa data for AMT-260, which is an important but expected clinical milestone for a development-stage biotech. Article Title
• Negative Sentiment: uniQure launched a proposed $150 million public offering, plus a potential $22.5 million greenshoe, which could dilute existing shareholders even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may weigh on sentiment, even though the trades were made under pre-arranged 10b5-1 plans. Article Title

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on QURE shares. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research note on Wednesday, June 17th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Finally, Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.92.

Institutional Investors Weigh In On uniQure

Hedge funds have recently modified their holdings of the stock. State Street Corp grew its holdings in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. raised its stake in shares of uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the last quarter. Orbimed Advisors LLC lifted its position in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after buying an additional 1,398,749 shares during the last quarter. Finally, MPM Bioimpact LLC bought a new position in shares of uniQure during the 4th quarter worth $33,062,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.